<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d464" origId="Nadolol"><sentence id="DrugDDI.d464.s0" origId="s0" text="When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics."><entity id="DrugDDI.d464.s0.e0" origId="s0.p3" charOffset="46-51" type="drug" text="drugs"/><entity id="DrugDDI.d464.s0.e1" origId="s0.p6" charOffset="70-110" type="drug" text="beta-adrenergic receptor blocking agents"/><entity id="DrugDDI.d464.s0.e2" origId="s0.p8" charOffset="112-123" type="drug" text="Anesthetics"/><entity id="DrugDDI.d464.s0.e3" origId="s0.p14" charOffset="177-196" type="drug" text="general anesthetics"/><pair id="DrugDDI.d464.s0.p0" e1="DrugDDI.d464.s0.e0" e2="DrugDDI.d464.s0.e1" interaction="?"/><pair id="DrugDDI.d464.s0.p1" e1="DrugDDI.d464.s0.e0" e2="DrugDDI.d464.s0.e2" interaction="?"/><pair id="DrugDDI.d464.s0.p2" e1="DrugDDI.d464.s0.e0" e2="DrugDDI.d464.s0.e3" interaction="?"/><pair id="DrugDDI.d464.s0.p3" e1="DrugDDI.d464.s0.e1" e2="DrugDDI.d464.s0.e2" interaction="?"/><pair id="DrugDDI.d464.s0.p4" e1="DrugDDI.d464.s0.e1" e2="DrugDDI.d464.s0.e3" interaction="?"/><pair id="DrugDDI.d464.s0.p5" e1="DrugDDI.d464.s0.e2" e2="DrugDDI.d464.s0.e3" interaction="?"/></sentence><sentence id="DrugDDI.d464.s1" origId="s1" text="Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;"><entity id="DrugDDI.d464.s1.e0" origId="s1.p15" charOffset="0-18" type="drug" text="Antidiabetic drugs"/><entity id="DrugDDI.d464.s1.e1" origId="s1.p19" charOffset="36-43" type="drug" text="insulin"/><pair id="DrugDDI.d464.s1.p0" e1="DrugDDI.d464.s1.e0" e2="DrugDDI.d464.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d464.s2" origId="s2" text="adjust dosage of antidiabetic drug accordingly."><entity id="DrugDDI.d464.s2.e0" origId="s2.p27" charOffset="17-34" type="drug" text="antidiabetic drug"/></sentence><sentence id="DrugDDI.d464.s3" origId="s3" text="Catecholamine-depleting drugs (e.g., reserpine): additive effect;"><entity id="DrugDDI.d464.s3.e0" origId="s3.p28" charOffset="24-29" type="drug" text="drugs"/><entity id="DrugDDI.d464.s3.e1" origId="s3.p31" charOffset="37-46" type="drug" text="reserpine"/><pair id="DrugDDI.d464.s3.p0" e1="DrugDDI.d464.s3.e0" e2="DrugDDI.d464.s3.e1" interaction="?"/></sentence><sentence id="DrugDDI.d464.s4" origId="s4" text="monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension)."/><sentence id="DrugDDI.d464.s5" origId="s5" text="Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic."><entity id="DrugDDI.d464.s5.e0" origId="s5.p53" charOffset="62-76" type="drug" text="beta-blockers"/></sentence><sentence id="DrugDDI.d464.s6" origId="s6" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction."><entity id="DrugDDI.d464.s6.e0" origId="s6.p72" charOffset="56-67" type="drug" text="epinephrine"/></sentence></document>